Abstract
Despite a decade of intensive preclinical research, the translation of cancer nanomedicine to the clinic has been slow. Here, we discuss how recent lessons learned from the successes with immuno-oncology therapies could be applied to cancer nanomedicine and how this may help to overcome some of the key technical challenges in this field.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
PLGA-based nanoparticles for the treatment of cancer: current strategies and perspectives
AAPS Open Open Access 01 August 2022
-
CC-01 (chidamide plus celecoxib) modifies the tumor immune microenvironment and reduces tumor progression combined with immune checkpoint inhibitor
Scientific Reports Open Access 20 January 2022
-
Nanoplatforms for Sepsis Management: Rapid Detection/Warning, Pathogen Elimination and Restoring Immune Homeostasis
Nano-Micro Letters Open Access 08 March 2021
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Shi, J., Kantoff, P. W., Wooster, R. & Farokhzad, O. C. Cancer nanomedicine: progress, challenges and opportunities. Nat. Rev. Cancer 17, 20–37 (2017).
Wilhelm, S. et al. Analysis of nanoparticle delivery to tumours. Nat. Rev. Mater. 1, 16014 (2016).
Lammers, T. et al. Cancer nanomedicine: is targeting our target? Nat. Rev. Mater. 1, 16076 (2016).
Jiang, W. et al. Designing nanomedicine for immuno-oncology. Nat. Biomed. Eng. 0029 (2017).
Kranz, L. M. et al. Systemic RNA delivery to dendritic cells exploits antiviral defense for cancer immunotherapy. Nature 534, 396–401 (2016).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Jiang, W., Yuan, H., Chan, C. et al. Lessons from immuno-oncology: a new era for cancer nanomedicine?. Nat Rev Drug Discov 16, 369–370 (2017). https://doi.org/10.1038/nrd.2017.34
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2017.34
This article is cited by
-
Engineering nanomaterial physical characteristics for cancer immunotherapy
Nature Reviews Bioengineering (2023)
-
PLGA-based nanoparticles for the treatment of cancer: current strategies and perspectives
AAPS Open (2022)
-
CC-01 (chidamide plus celecoxib) modifies the tumor immune microenvironment and reduces tumor progression combined with immune checkpoint inhibitor
Scientific Reports (2022)
-
Nanoplatforms for Sepsis Management: Rapid Detection/Warning, Pathogen Elimination and Restoring Immune Homeostasis
Nano-Micro Letters (2021)
-
Nanotechnology-based immunotherapies to combat cancer metastasis
Molecular Biology Reports (2021)